Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Healthcare Sector Analysis

UpdatedAug 27, 2026
DataAggregated Company Financials
Companies329
  • 7D1.1%
  • 3M8.6%
  • 1Y15.3%
  • YTD18.0%

In the last week, the Healthcare industry is up 1.1%, with Divi's Laboratories up 5.4%. This takes the industry's 12 month performance to a gain of 15%. Earnings are forecast to grow by 21% annually.

Sector Valuation and Performance

Has the Indian Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 27 Aug 2026₹37.3t₹6.5t₹837.8b31.5x44.6x5.7x
Sat, 25 Jul 2026₹34.9t₹6.2t₹793.0b31.4x44x5.7x
Mon, 22 Jun 2026₹33.4t₹6.1t₹806.7b32.3x41.4x5.4x
Wed, 20 May 2026₹33.0t₹6.0t₹772.3b31.2x42.8x5.5x
Fri, 17 Apr 2026₹30.2t₹5.9t₹780.6b29.8x38.7x5.1x
Sun, 15 Mar 2026₹29.7t₹5.9t₹780.6b27.4x38x5x
Tue, 10 Feb 2026₹29.7t₹5.8t₹773.9b29.9x38.4x5.1x
Thu, 08 Jan 2026₹31.0t₹5.7t₹771.4b32.8x40.2x5.4x
Sat, 06 Dec 2025₹30.5t₹5.7t₹768.0b33.4x39.7x5.3x
Mon, 03 Nov 2025₹30.6t₹5.5t₹739.5b34.4x41.4x5.5x
Wed, 01 Oct 2025₹29.6t₹5.5t₹730.3b36.1x40.6x5.4x
Fri, 29 Aug 2025₹30.0t₹5.5t₹730.0b35.5x41.1x5.5x
Sun, 27 Jul 2025₹31.1t₹5.4t₹734.8b36.7x42.4x5.8x
Tue, 24 Jun 2025₹29.1t₹5.3t₹728.3b35.5x40x5.5x
Thu, 22 May 2025₹28.9t₹5.3t₹710.3b35.2x40.7x5.5x
Sat, 19 Apr 2025₹28.1t₹5.2t₹680.2b34.2x41.4x5.4x
Mon, 17 Mar 2025₹26.6t₹5.2t₹680.1b30.2x39.2x5.1x
Wed, 12 Feb 2025₹27.7t₹5.2t₹667.7b34.8x41.4x5.3x
Fri, 10 Jan 2025₹29.8t₹5.0t₹648.5b39x46x5.9x
Sun, 08 Dec 2024₹29.2t₹5.0t₹643.1b39.1x45.4x5.8x
Tue, 05 Nov 2024₹29.0t₹4.9t₹616.7b42x47x5.9x
Thu, 03 Oct 2024₹29.3t₹4.9t₹605.3b44.1x48.5x6x
Sat, 31 Aug 2024₹28.6t₹4.9t₹605.1b40.6x47.2x5.9x
Mon, 29 Jul 2024₹26.4t₹4.7t₹560.5b38.8x47.1x5.6x
Wed, 26 Jun 2024₹24.0t₹4.6t₹548.5b35.8x43.7x5.2x
Fri, 24 May 2024₹23.3t₹4.7t₹550.5b34.6x42.4x5x
Sun, 21 Apr 2024₹22.5t₹4.6t₹512.8b34.4x43.9x4.9x
Tue, 19 Mar 2024₹22.3t₹4.6t₹512.5b33x43.5x4.9x
Thu, 15 Feb 2024₹22.7t₹4.5t₹519.1b35.9x43.8x5x
Sat, 13 Jan 2024₹21.3t₹4.4t₹477.0b37.5x44.7x4.8x
Mon, 11 Dec 2023₹19.6t₹4.4t₹476.1b33x41.1x4.4x
Wed, 08 Nov 2023₹18.3t₹4.3t₹458.4b32.2x40x4.3x
Fri, 06 Oct 2023₹18.3t₹4.3t₹451.6b33.5x40.5x4.3x
Sun, 03 Sep 2023₹17.7t₹4.2t₹450.7b31.5x39.3x4.2x
Price to Earnings Ratio

39.3x


Total Market Cap: ₹17.7tTotal Earnings: ₹450.7bTotal Revenue: ₹4.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Healthcare Sector Price to Earnings3Y Average 42.3x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 42.3x.
  • The industry is trading close to its 3-year average PS ratio of 5.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare sector?

IN Market0.83%
Healthcare1.10%
Medical Equipment4.40%
Life Sciences4.34%
Healthcare Services1.61%
Biotech0.87%
Pharma0.44%
Healthtech-4.10%
Industry PE
  • Investors are most optimistic about the Biotech industry which is trading above its 3-year average PE ratio of 71.7x.
    • Analysts are expecting annual earnings growth of 47.4%, which is higher than its past year's earnings growth of 28.6% per year.
  • Investors are most pessimistic about the Pharma industry, which is trading close to its 3-year average of 36.6x.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 47% over the next 5 years.
  • This is better than its past earnings growth rate of 29% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 18% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DIVISLAB Divi's Laboratories₹9.03k5.4%
+₹123.4b		45.8%PE81.9x
MANIPALHOS Manipal Health Enterprises₹795.006.7%
+₹66.0b		n/aPE119.7x
GLENMARK Glenmark Pharmaceuticals₹2.44k8.5%
+₹54.1b		25.0%PE38.3x
LAURUSLABS Laurus Labs₹1.89k4.7%
+₹46.0b		117.2%PE93.3x
ZYDUSLIFE Zydus Lifesciences₹1.15k4.1%
+₹45.4b		16.4%PE25.4x

Latest News

ZYDUSLIFE
₹1,189.20
Zydus Lifesciences
7D
7.4%
1Y
21.5%
Narrative Update • Aug 26

ZYDUSLIFE: COPD Launch And USFDA Outcomes Will Shape Balanced Outlook

Analysts have raised the Zydus Lifesciences price target from about ₹1,094 to roughly ₹1,196, citing updated assumptions that include slightly lower discount rates, modestly higher revenue growth and a higher future P/E multiple, partly offset by a somewhat lower profit margin outlook. What’s in the News for Zydus Lifesciences Zydus Lifesciences launched REVAHALE (Revefenacin), described as India’s first once daily nebulised Long Acting Muscarinic Antagonist for maintenance treatment of COPD, aimed at patients who need nebulised therapy and may struggle with handheld inhalers.
GLENMARK
₹2,460.00
Glenmark Pharmaceuticals
7D
5.4%
1Y
27.0%
MANIPALHOS
₹797.95
Manipal Health Enterprises
7D
10.2%
1Y
n/a
DIVISLAB
₹9,060.00
Divi's Laboratories
7D
5.7%
1Y
47.7%
Narrative Update • Aug 20

DIVISLAB: Upcoming June Quarter Results Will Support Bullish Outlook

Analysts have adjusted their price target on Divi's Laboratories from about ₹8,795 to about ₹10,953, reflecting updated views on its fair value, discount rate, revenue growth and profit margin assumptions, as well as the P/E they apply to the stock. What’s in the News for Divi's Laboratories Divi's Laboratories has scheduled a Board meeting on August 1, 2026.
KIMS
₹768.45
Krishna Institute of Medical Sciences
7D
-2.7%
1Y
4.2%
Narrative Update • Aug 19

KIMS: Follow On Equity Issuance And Governance Moves Will Shape Balanced Outlook

The analyst price target for Krishna Institute of Medical Sciences has been raised from ₹740 to ₹775, as analysts update their fair value view in line with refreshed assumptions for discount rate, revenue growth, profit margins and future P/E. What's in the News for Krishna Institute of Medical Sciences Board meeting scheduled on 3 Aug 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30 Jun 2026.
CONCORDBIO
₹1,481.90
Concord Biotech
7D
-6.0%
1Y
-12.6%
Narrative Update • Aug 18

CONCORDBIO: Higher Future P/E Will Likely Restrain Returns From Current Levels

Analysts have raised their fair value estimate for Concord Biotech from ₹1,020 to ₹1,268, citing updated assumptions for revenue growth, profit margins and future P/E levels as key drivers of the higher price target. What’s in the News for Concord Biotech A board meeting is scheduled on May 29, 2026 to review audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, consider a final equity dividend recommendation, review director appointments, and address other business matters.
500257
₹2,164.60
Lupin
7D
-1.7%
1Y
13.8%
ALKEM
₹5,320.00
Alkem Laboratories
7D
-1.5%
1Y
-1.0%
Narrative Update • Aug 17

ALKEM: Elevated P/E Will Persist Despite New Diabetes Drug Rollout

Analysts have raised their price target for Alkem Laboratories from ₹4,557.94 to ₹4,724.64, based on updated assumptions for the discount rate, revenue growth, profit margin and forward P/E multiples. What's in the News Alkem Laboratories has a board meeting scheduled on 14 August 2026 to consider and approve standalone and consolidated unaudited financial results for the quarter ended 30 June 2026.
MEDANTA
₹1,508.90
Global Health
7D
7.2%
1Y
7.8%
Narrative Update • Aug 15

MEDANTA: Guwahati Expansion And Higher Multiple Will Shape Balanced Outlook

Analysts have raised the Global Health price target from ₹1,258 to ₹1,411, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of this change. What’s in the News for Global Health Global Health Limited approved a revised construction plan for its upcoming Guwahati hospital at the board meeting held on July 30, 2026, increasing the proposed bed capacity from 400 beds to 650 beds.
AJANTPHARM
₹3,543.60
Ajanta Pharma
7D
-3.1%
1Y
41.3%
Narrative Update • Aug 14

AJANTPHARM: Rich Earnings Multiple And Recall Risk Will Restrain Upside

Ajanta Pharma's analyst price target has been revised to ₹3,149 from ₹2,701, with analysts citing updated fair value and P/E assumptions, as well as modest adjustments to the discount rate, revenue growth and profit margin inputs as the main factors behind this change. What's in the News for Ajanta Pharma Ajanta Pharma has scheduled a board meeting on July 30, 2026, to consider and approve unaudited consolidated and standalone financial results for the quarter ended June 30, 2026.
LAURUSLABS
₹1,929.40
Laurus Labs
7D
5.7%
1Y
123.8%
Narrative Update • Aug 14

LAURUSLABS: Future Returns Will Depend On Resilient Margins Supporting Elevated P E Multiples

The Laurus Labs analyst price target has been updated from ₹1,044.00 to about ₹1,486.29. This change is supported by analyst assumptions that reflect higher revenue growth, stronger profit margins and a modestly higher future P/E, while keeping the discount rate broadly similar.
506820
₹7,121.10
AstraZeneca Pharma India
7D
-5.1%
1Y
-14.4%
COHANCE
₹454.00
Cohance Lifesciences
7D
-4.5%
1Y
-47.9%
SUNPHARMA
₹1,913.30
Sun Pharmaceutical Industries
7D
0.5%
1Y
20.7%
Analysis Article • Aug 05

Results: Sun Pharmaceutical Industries Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

As you might know, Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) recently reported its quarterly numbers. Sun...
CIPLA
₹1,420.00
Cipla
7D
-1.3%
1Y
-10.1%
ANTHEM
₹924.60
Anthem Biosciences
7D
5.7%
1Y
13.1%
New Narrative • Jul 28

Capacity Expansion And Modalities Shift Will Support Stronger Long-Term Earnings Visibility

Catalysts About Anthem Biosciences Anthem Biosciences is a contract research, development and manufacturing organization with a large focus on CRDMO services and specialty ingredients across small molecules, peptides, fermentation and related modalities. What are the underlying business or industry changes driving this perspective?